
Celgene’s Otezla approved for NHS use
pharmafile | August 3, 2016 | News story | Research and Development, Sales and Marketing | Celgene, NHS, NICE, apremilast
NICE has published draft guidance recommending the use of Celgene’s Otezla (apremilast) for use on the NHS for treatment of patients suffering from severe psoriasis.
This decision comes after the organisation previously rejected the drug last year in November. It also came up against resistance from Germany’s cost-effectiveness agency IQWIG last year when it demanded more data to prove that the drug is worth its cost.
After conducting a rapid review in response to a patient access scheme submitted by Celgene, NICE is now recommending the drug as a treatment for severe chronic plaque psoriasis that has not responded to systemic therapy, or systemic therapy is contradicted or not tolerated, on the condition that the company provides it to the NHS at the discounted rate agreed to in the scheme
Analysts predict Otezla will achieve $1.3 billion in sales by 2018. Celgene’s expectations are even more ambitious; through exploring other possible applications for the drug such as rheumatoid arthritis treatment, the company anticipates up to $2 billion peak sales.
Matt Fellows
Related Content

Five Facts about NHS and primary care
1 Primary care is the front door to the NHS, but it extends well beyond …

Major funding opportunity opens for early cancer diagnostics
Up to £25.4m in funding is available for collaborative projects developing technologies to improve the …

Scots neonatal innovations target hearing loss and earlier care
Scottish healthcare teams are introducing a range of innovations aimed at improving outcomes for newborns, …






